Rodman & Renshaw initiated coverage of Rein Therapeutics (RNTX) with a Buy rating and $8 price target
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter